Key facts
- Enedra Therapeutics’s last known valuation is $2.7M (Jan 2024).
- It has raised $1.3M; the latest was Early Stage VC in May 2025.
- Notable investors include CD3 Leuven, Cancer Research Horizons, Deep Science Ventures, O2h Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Enedra Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Enedra Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enedra Therapeutics
Developer of cancer treatment drug designed to combat cancer heterogeneity in patients. The company's drug harnesses the power of synthetic lethality and advanced computational systems biology and discovers the first therapeutics that work against the complexity, and biological and mutational heterogeneity of cancer, enabling patients to battle cancer.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2021
- Employees
- 5
- Website
- enedratx.com/
- Ownership
- Privately Held (backing)
Enedra Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enedra Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enedra Therapeutics in its N-PORT filings yet. We sweep new filings monthly.